Rigel Pharmaceuticals
RIGL
113 hedge funds and large institutions have $272M invested in Rigel Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
58% more capital invested
Capital invested by funds: $172M → $272M (+$99.7M)
18% more funds holding
Funds holding: 96 → 113 (+17)
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
8% more call options, than puts
Call options by funds: $193K | Put options by funds: $179K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$2.74M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.42M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.28M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$989K |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$644K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$1.37M |
| 2 |
Renaissance Technologies
New York
|
-$1.14M |
| 3 |
BACM
Blue Arrow Capital Management
New York
|
-$1.02M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$960K |
| 5 |
BC
Broadfin Capital
New York
|
-$700K |
RIGL Hedge Fund Activity: Q1 2015 in Review
113 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2015, worth a combined $272M — up 58% from $172M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RIGL positions and 11 closed out — a net gain of 17 holders — while 35 added to existing stakes and 30 trimmed.
The largest buyer was Rhenman & Partners Asset Management, opening a new position worth an estimated $2.74M. The largest seller was Visium Asset Management, exiting entirely with an estimated $1.37M sold.
- 113 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2015, up from 96 in Q4 2014.
- Funds reported $272M of Rigel Pharmaceuticals stock for Q1 2015, up 58% quarter-over-quarter.
- 28 funds opened new Rigel Pharmaceuticals positions in Q1 2015 and 11 closed out, a net change of +17 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2015 was Rhenman & Partners Asset Management, an estimated $2.74M added.
- The largest Rigel Pharmaceuticals seller in Q1 2015 was Visium Asset Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q1 2015.